InvestorsHub Logo
Followers 3
Posts 204
Boards Moderated 0
Alias Born 10/18/2012

Re: None

Tuesday, 12/18/2012 8:23:55 AM

Tuesday, December 18, 2012 8:23:55 AM

Post# of 15662
"The confirmatory trial, AMP-516, failed to replicate the results of Study AMP-
502. In trial AMP-516 neither the primary endpoint of ETT duration nor any of the
secondary endpoints, including KPS, demonstrated a statistically significant effect of
Ampligen using the protocol-specified analyses."

That's why it's tanking. Great.